Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICUCW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SeaStar Medical Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SeaStar Medical Holding's regulatory disclosures and financial reporting.
Schlorff Eric reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp Chief Executive Officer Eric Schlorff received an equity grant in the form of restricted stock units. The award covers 10,288 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related grant rather than an open-market purchase.
According to the filing, the restricted stock units will vest in three equal installments on July 1, 2026, November 1, 2026, and March 1, 2027. After this grant, Schlorff holds 50,140 shares of SeaStar Medical common stock directly.
Chung Kevin reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp reported that Chief Medical Officer Kevin Chung received a grant of 7,202 shares of common stock in the form of restricted stock units. These RSUs were awarded at no cash cost to him as part of his compensation.
The award will vest in three equal installments on July 1, 2026, November 1, 2026, and March 1, 2027. After this grant, Chung directly holds 28,021 shares of SeaStar Medical common stock, showing his equity-based alignment with the company’s long-term performance.
Vincent Bernadette N reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Bernadette N. Vincent reported an equity compensation grant on a Form 4. She received 4,000 shares in the form of restricted stock units that will vest in full on July 1, 2027. These units were awarded at a stated price of $0.00 per share, reflecting a compensation grant rather than a market purchase. After this award, her directly held common stock position increased to 8,200 shares, indicating a relatively small but notable addition to her ownership stake through long-term incentive compensation.
Neuman John reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director John Neuman received an equity award of 4,000 shares of common stock in the form of restricted stock units (RSUs). The award was granted at a price of $0.00 per share as compensation, not as an open-market purchase.
The RSUs will vest in full on July 1, 2027, meaning Neuman must remain eligible through that date to receive the underlying shares. Following this grant, he holds 16,200 shares of SeaStar Medical common stock in total as reported in this filing.
Van Heel Kenneth reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Kenneth Van Heel received a grant of 4,000 restricted stock units. These RSUs vest in full on July 1, 2027, meaning he will receive the underlying shares if he remains eligible on that date. After this award, he directly holds 11,940 shares of common stock.
Baird Jennifer A reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Jennifer A. Baird received an equity grant of 4,000 shares in the form of restricted stock units. These RSUs relate to common stock with a par value of $0.0001 per share and will vest in full on July 1, 2027.
After this award, Baird holds a total of 10,620 shares of SeaStar Medical common stock directly, reflecting her updated ownership position as reported in this Form 4 filing.
SeaStar Medical Holding Corporation approved cash and stock retention bonuses for executives Eric Schlorff and Kevin Chung under a 2026 Retention Bonus Program. Schlorff’s bonus totals $200,000 and Chung’s totals $140,000, each split into three equal installments.
Each one-third payment is scheduled for July 1, 2026, November 1, 2026, and March 1, 2027, subject to continued employment on each vesting date. Executives will also receive an additional amount equal to 25% of each payment in shares of common stock under the 2022 Omnibus Incentive Plan, based on the closing share price on each vesting date.
If an executive departs before a vesting date, remaining payments are forfeited, while a separation without cause provides a pro‑rated amount of the next payment. The company executed individual 2026 Retention Bonus Program Agreements with both executives, filed as exhibits to this report.
SeaStar Medical Holding Corporation filed an amended report describing a new separation and release agreement with Mr. Green. The agreement, entered into on June 10, 2026, provides a mutual resolution of issues surrounding a previously disputed not-for-cause termination.
Under this new agreement, SeaStar Medical has agreed to pay Mr. Green more than was disclosed in the earlier report signed on August 19, 2025. The filing indicates all claims related to that dispute are being released as part of the mutual resolution.
SeaStar Medical Holding Corporation reported results from its annual stockholder meeting held on June 17, 2026. Stockholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of authorized shares of common stock available under the plan from 207,046 shares to 896,546 shares, supporting future equity-based compensation.
Stockholders also elected John Neuman as a Class I director to serve until the 2029 annual meeting. They ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved a proposal allowing adjournment or postponement of the meeting if additional proxy solicitation were needed.
SeaStar Medical Holding Corporation reported a quarterly net loss of $3.5 million on $0.5 million of revenue for the three months ended March 31, 2026. Revenue rose from $0.3 million a year earlier as QUELIMMUNE pediatric therapy adoption increased, but spending on research and development ($2.3 million) and general and administrative costs ($1.7 million) kept the company unprofitable.
Cash totaled $9.3 million with total assets of $11.3 million and an accumulated deficit of $155.2 million. Management states that existing cash will not fund operations for at least 12 months, raising substantial doubt about the company’s ability to continue as a going concern. SeaStar highlights ongoing commercialization of QUELIMMUNE, pivotal NEUTRALIZE-AKI and other adult trials, and notes a dismissed securities class action and a pending derivative suit.